Articles By Jack Cush, MD
ACR25 Best Abstracts - Day 3
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.
Read Article
ACR 2025 – Day 2 Report
Here are 3 abstracts that caught my eye on Day 2 at ACR25. Notably these have takeaway messages that should support your current practices.
Read Article
ACR25 Best Abstracts - Day 2
After a full day at the Chicago Convention center the RheumNow faculty have posted some of their favorite reports included these that they labeled as being the "best' of day 2.
Read Article
ACR25 - Day 1 Report
ACR 2025 began today in Chicago with throngs of rheumatologists, fellows, ARP members, APPs and pharma folk taking to the meeting halls and rooms for tons of novel content.
Read Article
ACR25 Best Abstracts - Day 1
The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expected but some of these are gems.
Read Article
Pre-ACR25 (10.24.2025)
Dr. Jack Cush reviews the news and info reports the day before ACR 2025
Read Article
Clinical and Genetic Effects of Neuropsychiatric Lupus
The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system.
Read Article
REPLENISH - Secukinumab Works in Polymyalgia Rheumatica
Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab in adults with polymyalgia rheumatica (PMR).
Read Article
Colchicine Ineffective in Long COVID
Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory markers.
Read Article
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss.
Read Article
